fashion -WSS

fashion

author：fashion 2025-09-28 01:39:15 - browse：8465

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Laying a path for careers in science

WSS

Pfizer is about to make a big push in cancer. Will investors listen?

CDC panel: People 65 and older should get a Covid spring booster shot

Bird flu outbreak in cows is latest avian flu curveball

Cell therapy fails to slow type 1 diabetes, but safety is established

Readout Newsletter: Beam, Prozac, "TechBio" and more

Study fuels hope CAR

entertainment

fashion

explore

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Medical leaders decry Supreme Court decision on affirmative action

Using force crossed my mind when examining a defiant young patient

Duchenne breakthrough therapy leaves behind pioneering families

Q&A: Jennifer Adair on making gene therapy available globally

How to save PrEP access — and even expand it

Exact Sciences stock tumbles despite strong cancer detection sales

Anesthesiologist group: stop taking Ozempic before surgery

Cue Health's Covid

focus

Bird flu outbreak in cows is latest avian flu curveball

CDC advisory group OKs chikungunya vaccine

Why rehabilitation engineers need to center patients in their research

Cholera vaccine supply gets boost as demand surges globally

Childhood vaccination ad campaign launches in the U.K.

Change Healthcare cyberattack shows risk of industry consolidation

focus

focus

hotspot

entertainment